Nissan Chemical
CORPORATION
WHERE IT ALL BEGINS

August 7, 2026

Presentation for Investors

1Q FY2026 (April 1, 2026 - June 30, 2026) Financial Results

Translation of presentation materials for the conference call held on August 7, 2026

Presented by DAIMON Hideki

Director, Senior Executive Vice President & CFO

Contents

Nissan Chemical CORPORATION

Contents

1Q FY2026 Financial Summary

1Q vs. 1Q FY2025	■ Sales up ¥8.9 billion (+13%) ■ OP up ¥3.8 billion (+21%) ■ Net Income up ¥2.9 billion (+21%) ■ **Sales, OP and Net Income achieved record-high results**
1Q vs. 1Q Outlook as of May 2026	■ Sales above target ¥9.7 billion ■ OP above target ¥5.1 billion ■ Net Income above target ¥3.0 billion
FY2026 Outlook	■ FY2026 Outlook for 1H and full year remain unchanged from those announced in May 2026 (Outlook by segment also remain unchanged)
Shareholder Returns	■ Share repurchase plan: ¥10.5 billion between May 2026 and March 2027 (as announced in May 2026)

1Q FY2026 Financial Summary YOY Change

Nissan Chemical CORPORATION

(¥billion)

	1Q FY2025 Actual	1Q FY2026 Actual	YOY Change
Sales	69.9	78.8	+8.9 (+13%)
Operating Profit	18.1	21.9	+3.8 (+21%)
Non-Operating Income/Expenses	0.0	1.7	+1.7
Foreign exchange Gains/Losses	-0.7	0.4	+1.1
Ordinary Income	18.1	23.6	+5.5 (+30%)
Extraordinary Income/Loss	0.0	0.0	0.0
Net Income[1]	13.9	16.8	+2.9 (+21%)
EBITDA[2]	21.4	25.5	+4.1
EPS (¥/share)	102.20	125.74	+23.54
OP Margin	25.9%	27.8%	+1.9pt
FX Rate (¥/$)	145	160	-

1. Net Income = Profit Attributable to Owners of Parent 2. EBITDA = Operating Profit + Depreciation and amortization

1Q FY2026 Financial Summary Compared to Outlook

(¥billion)

	1Q FY2026 Outlook	1Q FY2026 Actual	vs. Outlook
Sales	69.1	78.8	+9.7 (+14%)
Operating Profit	16.8	21.9	+5.1 (+30%)
Non-Operating Income/Expenses	1.4	1.7	+0.3
Foreign exchange Gains/Losses	0.0	0.4	+0.4
Ordinary Income	18.2	23.6	+5.4 (+30%)
Extraordinary Income/Loss	0.0	0.0	0.0
Net Income[1]	13.8	16.8	+3.0 (+22%)
EBITDA[2]	-	25.5	-
EPS (¥/share)	-	125.74	-
OP Margin	24.3%	27.8%	+3.5pt
FX Rate (¥/$)	150	160	-

1. Net Income = Profit Attributable to Owners of Parent 2. EBITDA = Operating Profit + Depreciation and amortization

Analysis of Changes in OP

(¥)

1Q

FY2026 Actual	FY2025 Actual	YOY Change	Outlook as of May 2026	vs. Outlook
21.9 billion	18.1 billion	+3.8 billion(+21%)	16.8 billion	+5.1 billion(+30%)

Segment			
Performance Materials	YOY Change	+2.5 billion	OP increase due to sales increase in Semis Materials and Inorganic Materials
	vs. Outlook	+2.4 billion	OP increase due to sales increase in Semis Materials and Inorganic Materials
Agrochemicals	YOY Change	+0.2 billion	OP increase due to sales increase in ROUNDUP, VERDAD and GRACIA etc.
	vs. Outlook	+1.6 billion	OP increase due to sales increase in Fluralaner, ALTAIR and GRACIA etc.
Chemicals	YOY Change	+0.2 billion	OP increase due to sales increase in Basic Chemicals
	vs. Outlook	-0.1 billion	OP decrease due to fixed cost etc.[1] up
Healthcare	YOY Change	+0.2 billion	OP increase due to sales increase in LIVALO and Custom Chemicals
	vs. Outlook	in line	

1. Fixed cost etc.: including inventory adjustment cost

Breakdown of Non-Operating Income/Expenses and Extraordinary Income/Losses

Nissan Chemical CORPORATION

（¥billion）

	1Q FY2025 Actual	1Q FY2026 Actual	YOY Change	1Q FY2026 Outlook
Interest income, dividend income	0.64	1.00	+0.36	0.92
Equity in earnings of affiliates	0.23	0.40	+0.17	0.63
Foreign exchange gains/losses[1]	-0.67	0.43	+1.10	0.00
Interest expense	-0.14	-0.13	+0.01	-0.18
Loss on disposal of non-current assets, others	-0.02	0.04	+0.06	0.03
Non-Operating Income/Expenses	0.04	1.74	+1.70	1.40
Extraordinary Income	0.00	0.00	0.00	0.00
Extraordinary Losses	0.00	0.00	0.00	0.00
Extraordinary Income/Losses	0.00	0.00	0.00	0.00

1. FX Rate (¥/$): 2025/3 149.53, 2025/6 144.82, 2026/3 159.93, 2026/6 162.45

Cash Flows

Nissan Chemical CORPORATION

Free cash flow in 1Q FY2026 was ¥15.1 billion, an increase of ¥2.1 billion from 1Q FY2025

(¥billion)

	1Q FY2025 Actual	1Q FY2026 Actual	YOY Change
CF from operating activities	16.3	21.2	+4.9
Income before income taxes & non-controlling interests	18.1	23.6	+5.5
Extraordinary losses (income)	0.0	0.0	0.0
Depreciation & amortization[1]	3.3	3.6	+0.3
Income taxes paid	-8.9	-7.4	+1.5
Working capital, others	3.8	1.4	-2.4
CF from investing activities	-3.3	-6.1	-2.8
Purchase of PPE[2]	-4.7	-4.4	+0.3
Purchase and sales of investment securities	0.0	-1.2	-1.2
Others	1.4	-0.5	-1.9
Free cash flow	13.0	15.1	+2.1
CF from financing activities	-7.7	-16.7	-9.0
Payout to shareholders (dividend)	-14.2	-17.7	-3.5
Payout to shareholders (share repurchase)	-2.9	-4.7	-1.8
Liabilities with Interest	9.5	-4.1	-13.6
Others	-0.1	9.8	+9.9
Effect of exchange rate change on cash & cash equivalents	0.7	0.2	-0.5
Change in cash & cash equivalents	6.1	-1.5	-7.6
Change in cash & cash equivalents resulting from change in scope of consolidation	0.0	0.9	+0.9
Cash & cash equivalents at end of period	33.5	35.2	+1.7

1. Including amortization of goodwill 2. Including intangible assets

Balance Sheets

(¥billion)

	2025/6	2026/3	2026/6	vs. 2026/3
Current assets	211.5	222.0	223.4	+1.4
Cash	33.5	35.7	35.2	-0.5
Accounts receivable	90.5	97.2	100.2	+3.0
Inventories	78.4	76.6	78.3	+1.7
Others	9.1	12.5	9.7	-2.8
Fixed assets	123.0	133.1	136.5	+3.4
Total PPE	73.8	77.0	78.8	+1.8
Intangible assets	13.1	12.8	12.1	-0.7
Investment securities	26.0	32.5	35.4	+2.9
Others	10.1	10.8	10.2	-0.6
Total assets	334.5	355.1	359.9	+4.8

	2025/6	2026/3	2026/6	vs. 2026/3
Liabilities	98.9	96.0	104.8	+8.8
Accounts payable	19.5	22.6	23.8	+1.2
Borrowings, CP & Bonds	49.8	38.4	44.3	+5.9
Others	29.6	35.0	36.7	+1.7
Net assets	235.6	259.1	255.1	-4.0
Shareholders' equity[1]	219.8	238.8	233.6	-5.2
Valuation difference on available-for-sale securities	8.1	11.5	12.3	+0.8
Foreign currency translation adjustment	2.8	3.1	3.4	+0.3
Remeasurements of defined benefit plans	1.5	1.9	1.9	0.0
Non-controlling interests	3.4	3.8	3.9	+0.1
Total liabilities & net assets	334.5	355.1	359.9	+4.8
Equity Ratio	69.4%	71.9%	69.8%	
Net D/E Ratio[2]	0.07	0.01	0.04	

Breakdown of Investment Securities

	2025/6	2026/3	2026/6	vs. 2026/3	Reference 2018/3
Listed shares[3] (Number of stocks held, Non-consolidated basis)	17.2 (24)	22.0 (24)	23.2 (24)	+1.2 (0)	30.0 (55)
Unlisted shares	2.2	2.5	3.6	+1.1	1.7
Subsidiaries/Associate shares	6.6	8.0	8.6	+0.6	6.8
Total	26.0	32.5	35.4	+2.9	38.5
Strategic shareholdings on net assets[4]	7.4%	8.6%	9.6%		17.0%

1. Change in shareholders' equity -5.2 = Net Income 16.8 – Dividend and others 22.0 .

2. Net D/E Ratio = (Borrowings + CP + Bonds - Cash) / Shareholders' equity

3. 2026/3 22.0 + Acquisition 0.0 + Sales and valuation difference 1.2 = 2026/6 23.2

4. Strategic shareholdings on net assets = strategic shareholdings (Non-consolidated basis, Listed shares + Unlisted shares) / Net assets (Consolidated basis)

Nissan Chemical CORPORATION

Contents

Overview

FY2026 Outlook by Segment (¥billion)





Performance Materials – Recent Financial Performance[1]



1. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method.

Reference [Presentation for R&D of Performance Materials](June 21, 2022)

Performance Materials

Sales by Subsegment, EBITDA Margin Trend
(No change from the May 2026 announcement)

- Semis Materials: High growth rates (YoY change) have been achieved from FY2024 onward, supported by the recovery of Semis market and our strong position in Asia following the temporary adjustment phase in FY2023
- DP Materials: Recovered after bottom-out in FY2022, have maintained stable sales as Cash Cow
- In terms of sales composition by subsegment, Semis Materials, a growth driver, significantly surpass DP Materials
- All of the subsegments' sales are increasing in FY2026, especially Semis Materials

Sales of Performance Materials by Subsegment, Segment Total EBITDA Margin[1] Trend



1. EBITDA Margin= (Operating Profit + Depreciation and amortization) / Sales

Performance Materials

Growth Outlook for our Semis Materials (No change from the May 2026 announcement)

Nissan Chemical CORPORATION

- Our Semis Materials sales growth rate is expected to be +20% or more (2024-2030 CAGR), exceeding the market growth rate of +10%
- Particularly for AI server applications, etc., our sales are expected to grow significantly in leading-edge and advanced generations

  The number of material layers tends to increase as technology generations advance

Sales Trend of Our Semis Materials[1]



1. SNOWTEX(polishing) (Inorganic Materials) and High-purity sulfuric acid (Chemicals) are not included

Sales growth of our Semis Materials exceeding market growth



Sales Image of our Semis Materials (Composition ratio by generation)



Leading-edge & advanced CAGR+22-24% , Legacy CAGR+13-15%

【Leading-edge】Logic：2nm and beyond, DRAM：Early 10nm generation and beyond, NAND：State-of-the-art as of 2025
【Advanced】Logic：7nm – 3nm, DRAM：Mid-10nm generation, NAND：128 layers and above, but below leading-edge 【Legacy】All other generations

Sales Growth Rate of Main Products

Nissan Chemical CORPORATION

- Semis Materials: 【1Q】Sales YOY +49%, Sales above target
- DP Materials: 【1Q】Sales YOY -4%, Sales in line with target
- Inorganic Materials: 【1Q】Sales YOY +27%, Sales above target

Main Products	1Q FY2026 Actual	
	YOY Change	vs. Outlook
Total Semis Materials	+49%	Above
ARC®	+35%	Above
Multi-layer process materials	+96%	Above
EUV materials	+23%	Slightly Below
Total Display Materials	-4%	In line
Total Inorganic Materials	+27%	Above
Total Segment	+26%	Above

1Q FY2026 Actual YOY Change

Nissan Chemical CORPORATION

(¥billion)

	1Q FY2025 Actual	1Q FY2026 Actual	YOY Change
Sales	25.9	32.6	+6.7
OP	8.2	10.7	+2.5

Fixed cost & others【1Q】up ¥1.6 billion

Semis Materials 【1Q】Sales & OP up

Semiconductor market growth across a wide range of technology nodes

Significant sales growth in Multi-layer process materials, ARC®, and EUV materials driven by higher customer fab utilization in Asia. Positive FX impact. 3D packaging process materials for back-end process sales solid

Fixed cost & others up ¥1.2 billion

Display Materials 【1Q】Sales & OP down

Display demand down, particularly in IT applications, due to rising memory prices

Photo IPS sales up: Lower demand for monitor and tablet applications due to rising memory prices, offset by a rebound in smartphone from the weak level in 1Q FY2025

VA for TV sales down

Inorganic Materials 【1Q】Sales & OP up

Sales up in SNOWTEX (non-polishing and polishing), Organo/Monomer Sol and Oilfield materials

SNOWTEX (polishing) sales up: Higher demand for CMP slurry raw materials driven by growing semiconductor demand

Organo/Monomer Sol sales up: Higher demand for ICT applications (data-center related) and enameled wire for EV

Performance Materials

1Q FY2026 Compared to Outlook

(¥billion)

	1Q FY2026 Outlook	1Q FY2026 Actual	vs. Outlook
Sales	**29.6**	**32.6**	**+3.0**
OP	**8.3**	**10.7**	**+2.4**

Fixed cost & others【1Q】less than outlook ¥1.0 billion (some Fixed cost & others in Semis shifted to 2Q or later)

Semis Materials

【1Q】Sales & OP above target

Sales above target, driven by Multi-layer process materials and ARC®, supported by higher customer fab utilization in Asia and positive FX impact

3D packaging process materials for back-end process sales in line with target

Fixed cost & others less than outlook ¥1.0 billion

Details: fixed cost less than outlook ¥0.2 billion
inventory adjustment cost less than ¥0.8 billion (shifted to 2Q or later)

Display Materials

【1Q】Sales in line with target, OP slightly below target

Photo IPS and VA sales in line with target

Inorganic Materials

【1Q】Sales & OP above target

Sales above target in SNOWTEX (non-polishing and polishing) and Organo/Monomer Sol

SNOWTEX (polishing) sales above target: Higher demand for CMP slurry raw materials driven by growing semiconductor demand

Organo/Monomer Sol sales above target: Higher demand for ICT applications (data-center related) and enameled wire for EV

Overview

Nissan Chemical CORPORATION

FY2026 Outlook by Segment (¥billion)





Agrochemicals – Recent Financial Performance[1]



1. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method.

Sales Growth Rate of Main Products (before discount)

【1Q】Sales YOY flat, Sales above target

Main Products (Agro: in order of FY2025 Sales amount)		Types	1Q FY2026 Actual	
			YOY Change	vs. Outlook
Agro	ROUNDUP[1]	Herbicide	**+18%**	**Above**
	ALTAIR	Herbicide	**+8%**	**Above**
	GRACIA	Insecticide	**+12%**	**Above**
	LEIMAY	Fungicide	**-44%**	**Slightly Below**
	TARGA	Herbicide	**-4%**	**In line**
	PERMIT	Herbicide	**-31%**	**Below**
	DITHANE	Fungicide	**-7%**	**In line**
	VERDAD[2]	Herbicide	**+569%**	**Above**
Animal Health	Fluralaner	Animal Health products	**-3%**	**Above**
Total Segment[3]		-	**0%**	**Above**

1. ROUNDUP AL for general household account for 34% of total ROUNDUP sales (1Q FY2026 Actual)
2. VERDAD was launched in 4Q FY2024
3. Total segment sales include discount

1Q FY2026 Actual Sales Composition*

*Before discount, excluding Fluralaner



Reference

[Agrochemicals Business Briefing](#) (January 13, 2026)

[ROUNDUP Business Briefing](#) (January 22, 2020)

Agrochemicals

1Q FY2026 YOY Change

(¥billion)

	1Q FY2025 Actual	1Q FY2026 Actual	YOY Change
Sales	**26.6**	**26.6**	**0.0**
OP	**8.6**	**8.8**	**+0.2**

【1Q】Sales flat, OP up

ROUNDUP	Sales up (ML and AL: volume down due to unfavorable weather in 1Q FY2025)
ALTAIR, VERDAD	Sales up (domestic: VERDAD sales expansion)
GRACIA	Sales up (domestic: sales up due to increased demand)
LEIMAY	Sales down (export: sales down due to decreased demand in Europe caused by weather conditions)
Fluralaner	Sales down (API: sales down, partial shipment shifted from FY2024 to 1Q FY2025, royalties: sales up, partly affected by positive FX impact)

1Q FY2026 Compared to Outlook

(¥billion)

	1Q FY2026 Outlook	1Q FY2026 Actual	vs. Outlook
Sales	23.3	26.6	+3.3
OP	7.2	8.8	+1.6

【1Q】Sales & OP above target

ROUNDUP	Sales above target (ML and AL: partial shipment shifted from 2Q)
ALTAIR, VERDAD	Sales above target (domestic: sales up due to increased demand)
GRACIA	Sales above target (domestic: sales up due to increased demand, export: sales up due to increased demand in Asia)
LEIMAY	Sales slightly below target (export: sales down due to decreased demand in Europe caused by weather conditions)
Fluralaner	Sales above target (API: sales up, royalties: sales up, partly affected by positive FX impact)

Agrochemicals

Main Products
(No change from the May 2026 announcement)

	Launch	Products	Application	Product development type	Notes
Existing products	2002	ROUNDUP	Herbicide	Acquired	Acquired domestic business from Monsanto, continuing to grow
	2008	LEIMAY	Fungicide	In-house	
	2008	STARMITE	Insecticide	In-house	
	2009	PULSOR (THIFLUZAMIDE)	Fungicide	Acquired	Acquired world business from Dow
	2010	ROUNDUP AL	Herbicide	In-house	For general household shower-type herbicide market, launched ROUNDUP AL Ⅱ in FY2016 and AL Ⅲ in FY2017
	2011	ALTAIR	Herbicide	In-house	For paddy rice. Launched in Korea in FY2011 and in Japan in FY2012
	2013	Fluralaner	Animal health product	In-house	Started to be supplied to MAH[1] as the API of BRAVECTO®
	2014	BRAVECTO®[2]	Veterinary medical product for companion animals	-	Launched in several countries in EU in April 2014, in USA in June 2014 and in Japan in July 2015
	2017	TRANSFORM™ / EXCEED™ / VIRESCO™	Insecticide	Licensed-in	Licensed from Dow
New products・Pipeline	2018	GRACIA	Insecticide	In-house	Effective against a wide range of serious pests, having less negative impact on honeybees. Launched in Korea in FY2018, in Japan in FY2019, and In India and Indonesia in FY2021. Expanding sales countries (expected peak sales ¥12.5 billion)
	2019	QUINTEC (QUINOXYFEN)	Fungicide	Acquired	Acquired world business from Corteva. Protective fungicide highly effective in controlling powdery mildew in fruits and vegetables
	2020	DITHANE (MANCOZEB)	Fungicide	Acquired	Acquired Japan and Korea business from Corteva in December 2020. Protective fungicide with significant efficacy against various plant diseases in fruits and vegetables
	2024	VERDAD (DIMESULFAZET) (NC-653)	Herbicide	In-house	For paddy rice. Effective against resistant weeds, having excellent safety to rice (expected peak sales ¥6.0 billion)
	2027	RYZONIC (IPTRIAZOPYRID) (NC-656)	Herbicide	In-house	Our first foliar application rice herbicide with excellent efficacy against resistant grass weeds (expected peak sales ¥15.0 billion[3])
	2028	PREXIO (FENMEZODITIAZ) (NC-520)	Insecticide	Joint development	Insecticide for paddy rice co-developed with BASF. Highly effective against planthoppers (expected peak sales ¥2.5 billion including mixture products)

Expected peak sales of new products
¥41.0 billion[3]

1. MAH: MSD Animal Health, the global animal health business unit of Merck 2. BRAVECTO®: the product name developed by MAH, containing the active substance Fluralaner
3. Expected peak sales of RYZONIC were revised upward from ¥10.0 billion to ¥15.0 billion in January 2026

Agrochemicals

API of Animal Health Product Fluralaner
(No change from the May 2026 announcement)

Nissan Chemical CORPORATION

- BRAVECTO® series and EXZOLT®, which contain the active pharmaceutical ingredient of Fluralaner invented by Nissan Chemical, are currently available in more than 100 countries.
- BRAVECTO® 's greatest feature is its effectiveness, which lasts up to 12 weeks (competing products last up to about 1 month)
- **Long-term supply agreement with MAH[1] for Fluralaner extended, joint R&D to create new animal health products (News release on April 11, 2025)**

I. Fluralaner → **II. BRAVECTO® for external parasites (Ecto)** / **III. BRAVECTO® for both internal and external parasites (Endecto)** / **IV. EXZOLT®**

I. Fluralaner

- Invented by Nissan Chemical and supplied to MAH[1] as the active pharmaceutical ingredient of BRAVECTO® and EXZOLT®
- Currently, BRAVECTO® series and EXZOLT® are available in more than 100 countries
- Compound patent
  - Fluralaner's compound patent expires in March 2025, but many countries have the patent term extension system
    - Some EU countries including UK, France, and Germany – already extended to February 2029
    - USA - extended to June 2027

II. BRAVECTO® for Ecto

- Developed and launched by MAH[1]
- Veterinary medical products providing 12 weeks[2] of continuous protection for dogs and cats against fleas and ticks with immediate effect, nearly 3 times longer than any monthly products in the market.
- Chewable tablet for dogs launched in:
  - April 2014 EU, thereafter, USA, Japan, etc.
  - July 2020 monthly chews for puppies in USA
- Spot-on solution for dogs and cats launched in:
  - July 2016 EU, thereafter, USA, Japan, etc.
- Injectable solution for dogs (BRAVECTO® Quantum)
  - Providing 12 months[3] of continuous protection
  - Launched in Australia in June 2024, and thereafter, in Europe, etc.
  - Launched in USA in August 2025
  - Launched in Japan in March 2026

III. BRAVECTO® for Endecto

- BRAVECTO® Plus
  - spot-on solution for cats
  - Launched in EU in July 2018, thereafter, USA, Japan, etc.
- BRAVECTO® TriUNO
  - Three-in-one chewable tablet for dogs
  - Providing 1 month of continuous protection
  - Approved in EU countries and Latin America in October 2024

IV. EXZOLT®

- Poultry medicine against red mite (administered via drinking water)
  - Launched in EU in 2017, thereafter, Korea, Middle East and Japan.
- Cattle medicine
  - Launched in Brazil in 2022, thereafter Mexico
- Sheep medicine
  - Launched in Australia and New Zealand in 2023

1. MAH: MSD Animal Health, the global animal health business unit of Merck
2. 8 weeks for *Rhipicephalus sanguineus* ticks
3. 11 months for *Rhipicephalus sanguineus* ticks

Agrochemicals

Sales Trend of Fluralaner
(No change from the May 2026 announcement)

Nissan Chemical CORPORATION

Nissan Chemical's Revenues are Consisted from Following Two Factors

・Sales of Fluralaner to MAH[1] as API[2] of BRAVECTO® and EXZOLT® products
・Running royalties received from MAH

FY2025 - FY2026 Quarterly Sales
(including royalties)



Our Fluralaner sales tend to be larger in 1H due to demand trends at MAH

FY2022 - FY2026 Sales Trend
(including royalties)



- FY2025 actual is +10% YOY, with API sales increase by +37% due to shipments shifted from FY2024.
  The actual exchange rate is ¥151/$.
- FY2026 outlook is flat YOY. The assumed exchange rate is ¥150/$.

BRAVECTO® series R&D

MAH is developing new parasiticides for pets with Fluralaner as the API, and expanding the number of the registered countries for existing products.

1. MAH: MSD Animal Health, the global animal health business unit of Merck　　2. API: Active Pharmaceutical Ingredient

Overview

FY2026 Outlook by Segment (¥billion)

Sales



OP



Chemicals – Recent Financial Performance[1]



1. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method.

Chemicals

1Q FY2026 YOY Change, Compared to Outlook

Nissan Chemical CORPORATION

YOY Change

(¥billion)

	1Q FY2025 Actual	1Q FY2026 Actual	YOY Change
Sales	9.3	10.5	+1.2
Fine Chemicals	3.4	4.0	+0.6
Basic Chemicals	5.9	6.5	+0.6
OP	0.7	0.9	+0.2

【1Q】Sales & OP up

In Fine Chemicals, OP flat due to fixed costs & others up despite sales up in TEPIC and environmental related products
In Basic Chemicals, OP up due to sales up in nitric acid products (recovery from mechanical trouble in 1Q FY2025) and high purity sulfuric acid (demand increase for semiconductors)

Compared to Outlook

(¥billion)

	1Q FY2026 Outlook	1Q FY2026 Actual	vs. Outlook
Sales	9.9	10.5	+0.6
Fine Chemicals	3.5	4.0	+0.5
Basic Chemicals	6.4	6.5	+0.1
OP	1.0	0.9	-0.1

【1Q】Sales above target, OP below target

In Fine Chemicals, OP above target due to sales above target in environmental related products and TEPIC etc.
In Basic Chemicals, OP below target due to fixed costs & others more than outlook despite sales above target in nitric acid products and urea/AdBlue®

Flow Chart of Selected Basic and Fine Chemicals Products (No change from the May 2026 announcement)

- Core products are ammonia related products and sulfuric acid related products
- FY2025 ammonia domestic production capacity share 11%
- Focus on high value-added products, such as high purity sulfuric acid, instead of pursuing scale



Overview

FY2026 Outlook by Segment (¥billion)





Healthcare – Recent Financial Performance[1·2]



1. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method
2. Organizational changes in Healthcare and Planning and Development division were implemented in April 2022.
   Figures for FY2020 and before are based on the pre-restructuring organization, while figures after FY2020 reflect the post-restructuring structure.

Healthcare

1Q FY2026 YOY Change, Compared to Outlook

Nissan Chemical CORPORATION

YOY Change

(¥billion)

	1Q FY2025 Actual	1Q FY2026 Actual	YOY Change
Sales	1.6	1.9	+0.3
OP	0.5	0.7	+0.2

【1Q】Sales & OP up

OP up due to sales up in Healthcare & Custom Chemicals

Compared to Outlook

(¥billion)

	1Q FY2026 Outlook	1Q FY2026 Actual	vs. Outlook
Sales	1.8	1.9	+0.1
OP	0.7	0.7	0.0

【1Q】Sales above target, OP in line with target

1Q FY2026 Financial Results YOY Change by Segment

(¥billion)

		1Q FY2025 Actual	1Q FY2026 Actual	YOY Change
Performance Materials	Sales	**25.9**	**32.6**	**+6.7** (+26%)
	OP	**8.2**	**10.7**	**+2.5** (+30%)
Agrochemicals	Sales	**26.6**	**26.6**	**0.0** (0%)
	OP	**8.6**	**8.8**	**+0.2** (+2%)
Chemicals	Sales	**9.3**	**10.5**	**+1.2** (+13%)
	OP	**0.7**	**0.9**	**+0.2** (+23%)
Healthcare	Sales	**1.6**	**1.9**	**+0.3** (+18%)
	OP	**0.5**	**0.7**	**+0.2** (+50%)
Trading, Others, Adjustment	Sales	**6.5**	**7.2**	**+0.7**
	OP	**0.1**	**0.8**	**+0.7**
Total	Sales	**69.9**	**78.8**	**+8.9** (+13%)
	OP	**18.1**	**21.9**	**+3.8** (+21%)

1. Including inter-segment sales/transfers
2. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay, Nippon Polytech, Nihon Hiryo, Adjustment: Planning & Development Division and others

1Q FY2026 Compared to Outlook by Segment

(¥billion)

		1Q FY2026 Outlook	1Q FY2026 Actual	vs. Outlook
Performance Materials	Sales	**29.6**	**32.6**	**+3.0** (+10%)
	OP	**8.3**	**10.7**	**+2.4** (+29%)
Agrochemicals	Sales	**23.3**	**26.6**	**+3.3** (+14%)
	OP	**7.2**	**8.8**	**+1.6** (+23%)
Chemicals	Sales	**9.9**	**10.5**	**+0.6** (+6%)
	OP	**1.0**	**0.9**	**-0.1** (-13%)
Healthcare	Sales	**1.8**	**1.9**	**+0.1** (+3%)
	OP	**0.7**	**0.7**	**0.0** (+6%)
Trading, Others, Adjustment	Sales	**4.5**	**7.2**	**+2.7**
	OP	**-0.4**	**0.8**	**+1.2**
Total	Sales	**69.1**	**78.8**	**+9.7** (+14%)
	OP	**16.8**	**21.9**	**+5.1** (+30%)

1. Including inter-segment sales/transfers
2. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay, Nippon Polytech, Nihon Hiryo, Adjustment: Planning & Development Division and others

Nissan Chemical CORPORATION

Contents

ESG

Nissan Chemical CORPORATION

E (Environment) **S** (Social)	April 2021	Announced its Diversity Statement and Diversity Vision
	May 2022	Decided to work on realization of carbon neutrality by 2050 Established new long-term target for reducing greenhouse gas (GHG) emissions (see p36)
	June 2022	Reduced GHG emissions by melamine production stop (26,000 tons, equivalent to about 7% of FY2018)
	June 2022	Established Climate Change Committee
	Sep 2025	"Nissan Bio-Park Nishi-Hongo (Toyama Plant)" and "Onoda Plant Biotope" Certified as "Nationally Certified Sustainably Managed Natural Sites" by the Ministry of the Environment
	Oct 2025	Published **"Integrated Report 2025"**
G (Governance)	April 2019	Established Nomination and Remuneration Advisory Committee as an optional advisory body of the Board of Directors
	June 2019	Introduced a performance-linked stock compensation plan called a Board Benefit Trust for Board of Directors, etc.
	April 2026	Partially revised the officers' remuneration system to increase the ratio of remuneration in stock. Before the revision: base remuneration 65%, performance-related remuneration 28%, remuneration in stock 7% After the revision[1]: base remuneration 50%, performance-related remuneration 30%, remuneration in stock 20%[2]
	June 2026	Updated and disclosed **"Corporate Governance Report"**
	June 2026	2 female Outside Directors appointed (re-elected), as a result, the Board of Directors includes 4 Outside Directors out of 10 2 female Outside Audit & Supervisory Board Member appointed (1 re-elected and 1 newly elected), as a result, the Board of Audit & Supervisory includes 3 Outside Directors out of 4

1.The breakdown of performance-related remuneration (90% profit-linked and 10% ESG-linked) remains unchanged.

2. Linked to ROE and TSR based metrics.

ESG Index and Third-party Recognition

Dow Jones Best-in-Class Asia Pacific Index

- April 2026
  Selected as a constituent for 8 consecutive years,
  including the former Dow Jones Sustainability Asia Pacific Index

S&P/JPX Carbon Efficient Index

- June 2025
  Selected as a constituent
  for 7 consecutive years

S&P/JPX Carbon Efficient Index

FTSE

- June 2026: Selected as a constituent of FTSE4Good Index Series, FTSE Blossom Japan Index for 7 consecutive years
- June 2026: Selected as a constituent of FTSE Blossom Japan Sector Relative Index for 5 consecutive years

1. FTSE Russell confirms that Nissan Chemical has been independently assessed according to the index criteria, and has satisfied the requirements to become a constituent of the FTSE Blossom Japan Sector Relative Index. The FTSE Blossom Japan Sector Relative Index is used by a wide variety of market participants to create and assess responsible investment funds and other products.

FTSE4Good | FTSE Blossom Japan | FTSE Blossom Japan Sector Relative Index

MSCI

- May 2025: Upgraded from A to AA (MSCI ESG Rating)
- June 2025: Selected as a constituent of MSCI Nihonkabu ESG Select Leaders Index for 2 consecutive years

2. THE INCLUSION OF NISSAN CHEMICAL CORPORATION IN ANY MSCI INDEX, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT OR PROMOTION OF NISSAN CHEMICAL CORPORATION BY MSCI OR ANY OF ITS AFFILIATES. THE MSCI INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI. MSCI AND THE MSCI INDEX NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI OR ITS AFFILIATES.z

2025 CONSTITUENT MSCI NIHONKABU ESG SELECT LEADERS INDEX

Morningstar

- December 2025: Selected as a constituent of Japan ex-REIT Gender Diversity Tilt Index for 3 consecutive years

Certified Health & Productivity Management Organization (White 500)

- March 2026: Acquired for 10 consecutive years

CDP

- January 2026:
  Selected as A List for CDP Water Security

CDP A List 2025

Participation in External Initiatives

TCFD TASK FORCE ON CLIMATE-RELATED FINANCIAL DISCLOSURES | TNFD Taskforce on Nature-related Financial Disclosures | GX League

"Childcare Support Company" Kurumin

- January 2023
  Acquired twice consecutively

Materiality (revised in Vista2027 Stage II)

Nissan Chemical CORPORATION

Specified materiality that we should engage to realize corporate image of 2027.
Aim to have sustainable growth with society by promoting initiatives.

1
Provision of New Value for Helping to Enrich People's Lives

Nissan Chemical Sustainable Agenda[1]

Rate of total sales of products and services that contribute to solving social issues in consolidated net sales

60% or more

(revised upward from maintain at least 55%)

1. A plan to pursue "what we can do for the future of the globe and human "by providing products and services that contribute to solving social issues

2
Strengthening of Nissan Chemical's Business Base

Personnel retention and trainings

Positive response rate in survey of employee attitude

65% or more

Promote Diversity

Proportion of female researchers

18% or more

3
Continuous Improvement of Responsible Care Activities

GHG Emission Target

Reduced by **30% or more** compared to FY2018

Our Materiality

Strengthening of Corporate Governance, Risk Management and Compliance

Reduction of GHG Emissions

- To achieve carbon neutrality by 2050, focus on initiatives such as improving production technology and adopting renewable energy, in addition to conventional efforts
- FY2027 GHG emissions target is expected to achieve at least a 30% reduction compared to FY2018 (Scope 1+2, non-consolidated basis). In FY2025, GHG emissions temporarily increased, reflecting the impact of mechanical trouble at the nitric acid plant in 1Q.

Our GHG emissions reduction target (Scope 1+2, non-consolidated basis)



Comparison of GHG emissions with general chemical manufacturers (consolidated basis)

(Thousands of tons -CO_2e)

FY	2019	2020	2021	2022	2023	2024
Nissan Chemical	346	337	364	346	305	315
Average of 4 major general chemical manufacturers	9,275	8,928	9,226	8,390	7,803	7,691

Initiatives in Medium-Term Plan Vista2027 (FY2022-2027)

- **Zero N_2O emissions from nitric acid plants (Planned investment of ¥830 million, variable cost of ¥70 million/year)**
- **Melamine production shutdown**
- **Converting fuels at Onoda Plant**
- **Promoting reduction of GHG emissions through full-scale introduction of ICP**
- **Reduction of CFC equipment**
- **Upgrade to energy-efficient equipment**

Contents

Quarterly Sales Trend by Segment (FY2023 - 1Q FY2026)

(¥billion)

	FY2023 Actual					FY2024 Actual					FY2025 Actual					FY2026 Actual	FY2026 Outlook			
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	1Q	2Q	2H	Total
Performance Materials	20.8	19.7	21.4	22.7	84.6	23.5	25.1	25.6	25.9	100.1	25.9	28.5	28.6	30.4	113.4	32.6	29.6	30.6	65.9	126.1
Agrochemicals	18.8	16.5	13.2	33.6	82.1	20.4	18.8	14.6	32.4	86.2	26.6	15.7	19.2	34.7	96.2	26.6	23.3	15.9	58.0	97.2
Chemicals	9.1	8.8	9.6	8.1	35.6	8.9	9.0	10.2	9.7	37.8	9.3	9.5	10.1	10.4	39.3	10.5	9.9	9.7	21.8	41.4
Fine Chemicals	3.0	3.0	3.0	2.6	11.6	3.1	3.2	3.4	3.2	12.9	3.4	3.4	3.2	3.7	13.7	4.0	3.5	3.3	7.2	14.0
Basic Chemicals	6.1	5.8	6.6	5.5	24.0	5.8	5.8	6.8	6.5	24.9	5.9	6.1	6.9	6.7	25.6	6.5	6.4	6.4	14.6	27.4
Healthcare	2.0	1.5	1.3	1.5	6.3	1.5	1.8	1.1	1.6	6.0	1.6	1.2	1.2	1.2	5.2	1.9	1.8	0.7	3.0	5.5
Trading	24.3	24.5	28.3	26.7	103.8	27.5	28.8	30.8	30.1	117.2	30.0	28.8	35.7	34.4	128.9	38.3	32.4	31.3	74.1	137.8
Others	6.4	5.9	6.0	11.8	30.1	6.3	5.7	8.8	8.4	29.2	7.9	6.9	7.7	9.3	31.8	8.9	8.8	10.4	18.3	37.5
Adjustment	-26.5	-26.1	-30.2	-33.0	-115.8	-29.4	-29.7	-34.5	-31.5	-125.1	-31.4	-30.4	-37.2	-36.2	-135.2	-40.0	-36.7	-36.2	-82.9	-155.8
Total	54.9	50.8	49.6	71.4	226.7	58.7	59.5	56.6	76.6	251.4	69.9	60.2	65.3	84.2	279.6	78.8	69.1	62.4	158.2	289.7

1. Including inter-segment sales/transfers
2. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay, Nippon Polytech, Nihon Hiryo, Adjustment: Planning & Development Division and others

Quarterly OP Trend by Segment (FY2023 - 1Q FY2026)

Nissan Chemical CORPORATION

(¥billion)

	FY2023 Actual					FY2024 Actual					FY2025 Actual					FY2026 Outlook
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q
Performance Materials	6.5	4.6	6.3	5.1	22.5	7.1	7.4	8.0	6.8	29.3	8.2	9.2	9.4	8.5	35.3	10.7
Agrochemicals	6.6	5.0	2.9	8.9	23.4	7.0	7.4	3.8	7.7	25.9	8.6	3.4	5.0	9.0	26.0	8.8
Chemicals	0.9	-1.0	0.4	-0.3	0.0	0.7	-1.0	0.5	0.2	0.4	0.7	-0.8	0.3	0.9	1.1	0.9
Healthcare	1.1	0.7	0.5	0.5	2.8	0.6	0.7	0.4	0.2	1.9	0.5	0.2	0.4	0.3	1.4	0.7
Trading	0.9	0.9	1.0	0.9	3.7	1.0	1.0	1.1	1.0	4.1	1.1	0.9	0.9	0.9	3.8	1.4
Others	0.2	0.0	-0.3	0.7	0.6	0.1	-0.1	0.1	0.5	0.6	0.5	0.3	0.2	1.0	2.0	0.5
Adjustment	-1.2	-1.1	-1.5	-1.0	-4.8	-2.1	-1.5	-1.1	-0.7	-5.4	-1.5	-1.7	-0.8	-2.0	-6.0	-1.1
Total	15.0	9.1	9.3	14.8	48.2	14.4	13.9	12.8	15.7	56.8	18.1	11.5	15.4	18.6	63.6	21.9

	FY2026 Outlook			
	1Q	2Q	2H	Total
Performance Materials	8.3	9.5	20.8	38.6
Agrochemicals	7.2	3.9	15.9	27.0
Chemicals	1.0	-0.7	1.0	1.3
Healthcare	0.7	-0.2	0.6	1.1
Trading	0.8	0.8	1.9	3.5
Others	0.4	0.5	0.8	1.7
Adjustment	-1.6	-1.9	-2.9	-6.4
Total	16.8	11.9	38.1	66.8

1. Trading: Nissei Corporation, Others: Nissan Butsuryu, Nissan Green & Landscape, Nissan Engineering, NC Tokyo Bay, Nippon Polytech, Nihon Hiryo, Adjustment: Planning & Development Division and others
2. FY2025- : New OP method adopted. FY2024 Actual have been restated based on the new method.

Main Products by Segment

Segment	Products		Main Applications
Performance Materials	**Semis Materials**	ARC®(ArF, KrF)	bottom anti-reflective coating for semiconductors
		OptiStack®	Multi-layer process materials for semiconductors (Si-HM: Silicon Hard Mask / SOC: Spin-On Carbon)
		EUV materials	EUV process materials (Under-Layer/Si-HM)
		3D packaging process materials	Temporary bonding materials
	Display Materials	SUNEVER	LCD alignment coating
		(Main Mode) VA (Vertical Alignment)	TV
		IPS (In-Plane Switching)	Smartphone, Tablet, PC, Monitor, Automobile
	Inorganic Materials	SNOWTEX	water dispersed colloidal silica sol for polishing silicon wafers, special steel sheets
		Organo/Monomer Sol	film coating, antistatic interference shielding, electronic printing materials, resin additive
		Oilfield materials	for enhancing oil recovery
Agrochemicals	**Herbicide**	TARGA	soybean, rapeseed, sugarbeet
		PERMIT	corn, sugarcane, rice
		ROUNDUP	non-selective herbicide for orchard, noncrop land
		ALTAIR	rice
		VERDAD	rice
	Insecticide	GRACIA	vegetables, tea, fruits
	Fungicide	LEIMAY	potato, vegetables, grape
		DITHANE (MANCOZEB)	fruits, vegetables
	Animal health product	Fluralaner	active substance of BRAVECTO® (veterinary medical product for dogs and cats) and EXZOLT® (for poultry, cattle, and sheep)
Chemicals	**Fine Chemicals**	TEPIC	epoxy compound for LED sealants, solder resist, painting
		Melamine cyanurate	flame retardant
		Environmental related products	agent used for sterilizing, disinfectant for swimming pool and septic tanks, etc.
		FINEOXOCOL	cosmetics, lubricants, adhesive
	Basic Chemicals	AdBlue®	solution of urea in demineralised water for diesel vehicles to reduce NOx
		High purity sulfuric acid	agents used for cleaning semiconductors
		Ammonia, Sulfuric acid, Nitric acid, Urea	
Healthcare		LIVALO API	anti-cholesterol drug
		Custom Chemicals	custom manufacturing and solution proposal business for pharmaceutical companies

1. ARC® and OptiStack® are registered trademark of Brewer Science, Inc.
2. BRAVECTO® and EXZOLT® are registered trademark of a subsidiary of Merck & Co., Inc.
3. AdBlue® is a registered trademark of German Automobile Industry Association (Verband der Automobilindustrie).

Disclaimer and Copyright

The forward looking statements in this material are based on information available at the time of preparation of the material. Although they reflect our current expectations, these statements are not guarantees of future performance, but include a number of risks and uncertainties. Actual results may largely differ from these statements due to various factors which may be beyond company control.

No information in this material is provided as an offer to buy or sell the shares of the company. We urge users of the material to make investment decision based upon own judgment.